The University of Chicago Header Logo

Peter H. O'Donnell

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Milowsky MI, O'Donnell PH, Hoimes CJ, Petrylak DP, Flaig TW, Moon HH, Friedlander TW, Mar N, McKay RR, Srinivas S, Gravis G, Ramamurthy C, Bupathi M, Bracarda S, Wright P, Hepp Z, Carret AS, Yu Y, Dillon R, Kataria R, Beaumont JL, Purnajo I, Rosenberg JE. Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. J Clin Oncol. 2024 Jan 12; JCO2301547. PMID: 38215355.
      Citations:    Fields:    
    2. Lynch C, Sweis RF, Modi P, Agarwal PK, Szmulewitz RZ, Stadler WM, O'Donnell PH, Liauw SL, Pitroda SP. Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 Jan 09. PMID: 38228414.
      Citations:    Fields:    
    3. Grande E, Arranz JÁ, De Santis M, Bamias A, Kikuchi E, Del Muro XG, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Schutz FA, Puente J, Li JR, O'Donnell PH, Kalebasty AR, Ye D, Mariathasan S, Bene-Tchaleu F, Bernhard S, Lee C, Davis ID, Galsky MD. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol. 2024 Jan; 25(1):29-45. PMID: 38101433.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    4. Kanegusuku ALG, Chan CW, O'Donnell PH, Yeo KJ. Implementation of pharmacogenomics testing for precision medicine. Crit Rev Clin Lab Sci. 2024 Mar; 61(2):89-106. PMID: 37776898.
      Citations:    Fields:    
    5. Doroshow DB, O'Donnell PH, Hoffman-Censits JH, Gupta SV, Vaishampayan U, Heath EI, Garcia P, Zhao Q, Yu M, Milowsky MI, Galsky MD. Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations. JCO Precis Oncol. 2023 Jul; 7:e2300095. PMID: 37410974.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    6. O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto Rey JP, Ferrario C, Carret AS, Yu Y, Guseva M, Homet Moreno B, Rosenberg JE. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023 09 01; 41(25):4107-4117. PMID: 37369081; PMCID: PMC10852367.
      Citations: 11     Fields:    Translation:Humans
    7. Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper TC, McLeod HL, O'Donnell PH, Relling MV, Rudek MA, Sissung TM, Smith DM, Sparreboom A, Swain SM, Walko CM. DPYD Testing: Time to Put Patient Safety First. J Clin Oncol. 2023 05 20; 41(15):2701-2705. PMID: 36821823; PMCID: PMC10414691.
      Citations: 4     Fields:    Translation:Humans
    8. Chen T, O'Donnell PH, Middlestadt M, Ruhnke GW, Danahey K, van Wijk XMR, Choksi A, Knoebel R, Hartman S, Yeo KJ, Friedman PN, Ratain MJ, Nutescu EA, O'Leary KJ, Perera MA, Meltzer DO. Implementation of pharmacogenomics into inpatient general medicine. Pharmacogenet Genomics. 2023 02 01; 33(2):19-23. PMID: 36729768.
      Citations: 3     Fields:    Translation:Humans
    9. Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Lee JL, Fong L, Vogelzang NJ, Necchi A, Petrylak DP, Plimack ER, Xu JZ, Imai K, Moreno BH, Bellmunt J, de Wit R, O'Donnell PH, Fradet Y, Climent MA. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol. 2023 03; 34(3):289-299. PMID: 36494006.
      Citations: 8     Fields:    Translation:Humans
    10. Damrauer JS, Beckabir W, Klomp J, Zhou M, Plimack ER, Galsky MD, Grivas P, Hahn NM, O'Donnell PH, Iyer G, Quinn DI, Vincent BG, Quale DZ, Wobker SE, Hoadley KA, Kim WY, Milowsky MI. Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nat Commun. 2022 11 04; 13(1):6658. PMID: 36333289; PMCID: PMC9636269.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    11. Lacouture ME, Patel AB, Rosenberg JE, O'Donnell PH. In Reply. Oncologist. 2022 Oct 01; 27(10):e827-e828. PMID: 36036599; PMCID: PMC9526498.
      Citations:    Fields:    Translation:Humans
    12. Saulsberry L, Singh L, Pruitt J, Ward C, Wake DT, Gibbons RD, Meltzer DO, O'Donnell PH, Cruz-Knight W, Hulick PJ, Dunnenberger HM, David SP. Effect Modification by Social Determinants of Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions within an Integrated U.S. Healthcare System. J Pers Med. 2022 Jul 15; 12(7). PMID: 35887642; PMCID: PMC9319564.
      Citations: 1     
    13. Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, Pyzer AR, Trujillo J, Derman BA, O'Donnell P, Jakubowiak A, Kindler HL, Bestvina C, Gajewski TF. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6). PMID: 35732350; PMCID: PMC9226983.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
    14. Bellmunt J, de Wit R, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O'Donnell PH, Powles T, Plimack ER, Bajorin DF, Balar AV, Castellano D, Choueiri TK, Gerritsen W, Gurney H, Quinn DI, Vuky J, Vogelzang NJ, Cristescu R, Lunceford J, Saadatpour A, Loboda A, Ma J, Rajasagi M, Godwin JL, Homet Moreno B, Grivas P, Fradet Y, Climent MA, Culine S. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clin Cancer Res. 2022 05 13; 28(10):2050-2060. PMID: 35247908.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    15. Truong TM, Apfelbaum JL, Schierer E, Danahey K, Borden BA, Karrison T, Shahul S, Anitescu M, Gerlach R, Knoebel RW, Meltzer DO, Ratain MJ, O'Donnell PH. Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care. Pharmacogenet Genomics. 2022 04 01; 32(3):79-86. PMID: 34570085; PMCID: PMC8940738.
      Citations:    Fields:    Translation:Humans
    16. Reizine NM, O'Donnell PH. Modern developments in germline pharmacogenomics for oncology prescribing. CA Cancer J Clin. 2022 07; 72(4):315-332. PMID: 35302652; PMCID: PMC9262778.
      Citations: 3     Fields:    Translation:HumansCells
    17. Lacouture ME, Patel AB, Rosenberg JE, O'Donnell PH. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. Oncologist. 2022 03 11; 27(3):e223-e232. PMID: 35274723; PMCID: PMC8914492.
      Citations: 14     Fields:    Translation:Humans
    18. Truong TM, Apfelbaum JL, Danahey K, Schierer E, Ludwig J, George D, House L, Karrison T, Shahul S, Anitescu M, Choksi A, Hartman S, Knoebel RW, van Wijk XMR, Yeo KJ, Meltzer DO, Ratain MJ, O'Donnell PH. Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial. Anesth Analg. 2022 11 01; 135(5):929-940. PMID: 35213469; PMCID: PMC9402808.
      Citations:    Fields:    Translation:Humans
    19. McGregor B, O'Donnell PH, Balar A, Petrylak D, Rosenberg J, Yu EY, Quinn DI, Heath EI, Campbell M, Hepp Z, McKay C, Steinberg J, Regnault A, Mazerolle F, Galsky MD. Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. Eur Urol. 2022 05; 81(5):515-522. PMID: 35168844; PMCID: PMC9385268.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    20. Reizine NM, Danahey K, Truong TM, George D, House LK, Karrison TG, van Wijk XMR, Yeo KJ, Ratain MJ, O'Donnell PH. Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer. 2022 Apr 15; 128(8):1649-1657. PMID: 35090043; PMCID: PMC9153953.
      Citations: 1     Fields:    Translation:Humans
    21. Saulsberry L, Danahey K, Middlestadt M, O'Leary KJ, Nutescu EA, Chen T, Lee JC, Ruhnke GW, George D, House L, van Wijk XMR, Yeo KJ, Choksi A, Hartman SW, Knoebel RW, Friedman PN, Rasmussen LV, Ratain MJ, Perera MA, Meltzer DO, O'Donnell PH. Applicability of Pharmacogenomically Guided Medication Treatment during Hospitalization of At-Risk Minority Patients. J Pers Med. 2021 Dec 10; 11(12). PMID: 34945816; PMCID: PMC8709436.
      Citations: 1     
    22. David SP, Singh L, Pruitt J, Hensing A, Hulick P, Meltzer DO, O'Donnell PH, Dunnenberger HM. The Contribution of Pharmacogenetic Drug Interactions to 90-Day Hospital Readmissions: Preliminary Results from a Real-World Healthcare System. J Pers Med. 2021 Nov 23; 11(12). PMID: 34945714; PMCID: PMC8705172.
      Citations: 3     
    23. Tang NY, Pei X, George D, House L, Danahey K, Lipschultz E, Ratain MJ, O'Donnell PH, Yeo KJ, van Wijk XMR. Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform. J Appl Lab Med. 2021 11 01; 6(6):1505-1516. PMID: 34263311; PMCID: PMC8561785.
      Citations: 4     Fields:    Translation:Humans
    24. Saulsberry L, Danahey K, Borden BA, Lipschultz E, Traore M, Ratain MJ, Meltzer DO, O'Donnell PH. Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics. NPJ Genom Med. 2021 Nov 01; 6(1):90. PMID: 34725343; PMCID: PMC8560901.
      Citations: 4     
    25. Reizine N, Danahey K, Schierer E, Liu P, Middlestadt M, Ludwig J, Truong TM, van Wijk XMR, Yeo KJ, Malec M, Ratain MJ, O'Donnell PH. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients. Oncologist. 2021 11; 26(11):e2042-e2052. PMID: 34423496; PMCID: PMC8571740.
      Citations: 5     Fields:    Translation:Humans
    26. Lipschultz E, Danahey K, Truong TM, Schierer E, Volchenboum SL, Ratain MJ, O'Donnell PH. Creation of a pharmacogenomics patient portal complementary to an existing institutional provider-facing clinical decision support system. JAMIA Open. 2021 Jul; 4(3):ooab067. PMID: 34458686; PMCID: PMC8390782.
      Citations: 3     
    27. Borden BA, Jhun EH, Danahey K, Schierer E, Apfelbaum JL, Anitescu M, Knoebel R, Shahul S, Truong TM, Ratain MJ, O'Donnell PH. Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application. Pharmacogenomics J. 2021 12; 21(6):691-711. PMID: 34376788; PMCID: PMC9267777.
      Citations: 1     Fields:    Translation:Humans
    28. Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518. PMID: 34168049.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    29. Tatjana A, Tjota MY, O'Donnell PH, Eggener SE, Agarwal PK, Haridas R, Segal J, Wang P. EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma. Virchows Arch. 2022 Feb; 480(2):487-492. PMID: 34128116.
      Citations: 1     Fields:    Translation:Humans
    30. Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV, Loriot Y. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):872-882. PMID: 33991512.
      Citations: 60     Fields:    Translation:HumansCTClinical Trials
    31. Bellmunt J, Hussain M, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T, IMvigor010 Study Group, Gschwend JE, Albers P, Bedke J. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 04; 22(4):525-537. PMID: 33721560; PMCID: PMC8495594.
      Citations: 103     Fields:    Translation:Humans
    32. Reid P, Danahey K, Lopez Velazquez M, Ratain MJ, O'Donnell PH. Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis. Clin Exp Rheumatol. 2021 Nov-Dec; 39(6):1385-1393. PMID: 33506753.
      Citations: 1     Fields:    Translation:Humans
    33. Reizine N, Vokes EE, Liu P, Truong TM, Nanda R, Fleming GF, Catenacci DVT, Pearson AT, Parsad S, Danahey K, van Wijk XMR, Yeo KJ, Ratain MJ, O'Donnell PH. Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. Ther Adv Med Oncol. 2020; 12:1758835920974118. PMID: 33414846; PMCID: PMC7750903.
      Citations: 4     
    34. Truong TM, Lipschultz E, Schierer E, Danahey K, Ratain MJ, O'Donnell PH. Patient insights on features of an effective pharmacogenomics patient portal. Pharmacogenet Genomics. 2020 12; 30(9):191-200. PMID: 33017129; PMCID: PMC7539134.
      Citations: 5     Fields:    Translation:Humans
    35. O'Donnell PH. Incorporating preemptive pharmacogenomic testing into the clinical setting. Clin Adv Hematol Oncol. 2020 09; 18(9):526-529. PMID: 33006581.
      Citations: 1     Fields:    Translation:Humans
    36. Zhang T, Harrison MR, O'Donnell PH, Alva AS, Hahn NM, Appleman LJ, Cetnar J, Burke JM, Fleming MT, Milowsky MI, Mortazavi A, Shore N, Sonpavde GP, Schmidt EV, Bitman B, Munugalavadla V, Izumi R, Patel P, Staats J, Chan C, Weinhold KJ, George DJ. A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Cancer. 2020 10 15; 126(20):4485-4497. PMID: 32757302; PMCID: PMC7590121.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    37. Vuky J, Balar AV, Castellano D, O'Donnell PH, Grivas P, Bellmunt J, Powles T, Bajorin D, Hahn NM, Savage MJ, Fang X, Godwin JL, Frenkl TL, Homet Moreno B, de Wit R, Plimack ER. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2020 08 10; 38(23):2658-2666. PMID: 32552471.
      Citations: 83     Fields:    Translation:HumansCTClinical Trials
    38. Christian C, Borden BA, Danahey K, Yeo KJ, van Wijk XMR, Ratain MJ, O'Donnell PH. Pharmacogenomic-Based Decision Support to Predict Adherence to Medications. Clin Pharmacol Ther. 2020 08; 108(2):368-376. PMID: 32236960; PMCID: PMC7363565.
      Citations: 5     Fields:    Translation:Humans
    39. Grivas P, Plimack ER, Balar AV, Castellano D, O'Donnell PH, Bellmunt J, Powles T, Hahn NM, de Wit R, Bajorin DF, Ellison MC, Frenkl TL, Godwin JL, Vuky J. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. Eur Urol Oncol. 2020 06; 3(3):351-359. PMID: 32423837; PMCID: PMC8246631.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    40. O'Donnell PH, Trubetskoy V, Nurhussein-Patterson A, Hall JP, Nath A, Huo D, Fleming GF, Ingle JN, Abramson VG, Morrow PK, Storniolo AM, Forero A, Van Poznak C, Liu MC, Chang JC, Merkel DE, Peppercorn JM, Rugo HS, Dees EC, Hahn OM, Hoffman PC, Rosner GL, Huang RS, Ratain MJ, Cox N, Olopade OI, Wolff AC, Dolan ME, Nanda R, Translational Breast Cancer Research Consortium (TBCRC). Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633. PMID: 32378051.
      Citations: 6     Fields:    Translation:Humans
    41. Seftel MD, Kuxhausen M, Burns L, Chitphakdithai P, Confer D, Kiefer D, Lee S, Logan B, O'Donnell P, Pulsipher M, Shah NN, Switzer G, Shaw BE. Clonal Hematopoiesis in Related Allogeneic Transplant Donors: Implications for Screening and Management. Biol Blood Marrow Transplant. 2020 06; 26(6):e142-e144. PMID: 32147534; PMCID: PMC7440392.
      Citations: 1     Fields:    Translation:Humans
    42. O'Donnell PH, Arkenau HT, Sridhar SS, Ong M, Drakaki A, Spira AI, Zhang J, Gordon MS, Degboe AN, Gupta AK, Mukhopadhyay P, Huang W, Abdullah SE, Angra N, Roskos LK, Guo X, Friedlander T. Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. Cancer. 2020 01 15; 126(2):432-443. PMID: 31581306.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    43. Truong TM, Lipschultz E, Danahey K, Schierer E, Ratain MJ, O'Donnell PH. Assessment of Patient Knowledge and Perceptions of Pharmacogenomics Before and After Using a Mock Results Patient Web Portal. Clin Transl Sci. 2020 01; 13(1):78-87. PMID: 31490020; PMCID: PMC6951853.
      Citations: 9     Fields:    Translation:Humans
    44. Hernandez W, Danahey K, Pei X, Yeo KJ, Leung E, Volchenboum SL, Ratain MJ, Meltzer DO, Stranger BE, Perera MA, O'Donnell PH. Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation. Pharmacogenomics J. 2020 02; 20(1):126-135. PMID: 31506565; PMCID: PMC7184888.
      Citations: 8     Fields:    Translation:Humans
    45. Truong TM, Apfelbaum J, Shahul S, Anitescu M, Danahey K, Knoebel RW, Liebovitz D, Karrison T, van Wijk XMR, Yeo KJ, Meltzer D, Ratain MJ, O'Donnell PH. The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. Clin Pharmacol Ther. 2019 12; 106(6):1179-1183. PMID: 31433489; PMCID: PMC7214100.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    46. Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019 10 10; 37(29):2592-2600. PMID: 31356140; PMCID: PMC6784850.
      Citations: 196     Fields:    Translation:HumansCTClinical Trials
    47. Jhun EH, Ratain MJ, O'Donnell PH, Apfelbaum JL, Dickerson DM, Shahul S, Knoebel R, Danahey K. Pharmacogenomic considerations for medications in the perioperative setting. Pharmacogenomics. 2019 07; 20(11):813-827. PMID: 31411557; PMCID: PMC6949515.
      Citations: 3     Fields:    Translation:Humans
    48. Friedman PN, Shaazuddin M, Gong L, Grossman RL, Harralson AF, Klein TE, Lee NH, Miller DC, Nutescu EA, O'Brien TJ, O'Donnell PH, O'Leary KJ, Tuck M, Meltzer DO, Perera MA. The ACCOuNT Consortium: A Model for the Discovery, Translation, and Implementation of Precision Medicine in African Americans. Clin Transl Sci. 2019 05; 12(3):209-217. PMID: 30592548; PMCID: PMC6510376.
      Citations: 23     Fields:    Translation:HumansCells
    49. Borden BA, Lee SM, Danahey K, Galecki P, Patrick-Miller L, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, Stadler WM, Kavitt RT, Meltzer DO, Ratain MJ, O'Donnell PH. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. Pharmacogenomics J. 2019 12; 19(6):528-537. PMID: 30713337; PMCID: PMC6980369.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    50. Borden BA, Galecki P, Wellmann R, Danahey K, Lee SM, Patrick-Miller L, Sorrentino MJ, Nanda R, Koyner JL, Polonsky TS, Stadler WM, Mulcahy C, Kavitt RT, Ratain MJ, Meltzer DO, O'Donnell PH. Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study. Pharmacogenet Genomics. 2019 02; 29(2):31-38. PMID: 30531377.
      Citations: 12     Fields:    Translation:Humans
    51. Lee YM, Danahey K, Knoebel RW, Ratain MJ, Meltzer DO, O'Donnell PH. Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing. Pharmacogenet Genomics. 2019 02; 29(2):23-30. PMID: 30531378.
      Citations: 6     Fields:    Translation:Humans
    52. Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer. 2019 02 15; 125(4):533-540. PMID: 30570744; PMCID: PMC6590473.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    53. Leng J, Akthar AS, Szmulewitz RZ, O'Donnell PH, Sweis RF, Pitroda SP, Smith N, Steinberg GD, Liauw SL. Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18. PMID: 30392939.
      Citations: 2     Fields:    Translation:Humans
    54. Wellmann R, Borden BA, Danahey K, Nanda R, Polite BN, Stadler WM, Ratain MJ, O'Donnell PH. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065. PMID: 29742281; PMCID: PMC6354920.
      Citations: 7     Fields:    Translation:Humans
    55. Deng B, Park JH, Ren L, Yew PY, Kiyotani K, Antic T, O'Connor K, O'Donnell PH, Nakamura Y. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. Cancer Rep (Hoboken). 2018 06; 1(1):e1002. PMID: 32729250; PMCID: PMC7941587.
      Citations: 7     Fields:    Translation:HumansCells
    56. O'Donnell PH, Reynolds KS. Breaking Down Barriers to Effective Patient Care. Clin Pharmacol Ther. 2018 03; 103(3):360-364. PMID: 29417567.
      Citations:    Fields:    Translation:Humans
    57. Danahey K, Borden BA, Furner B, Yukman P, Hussain S, Saner D, Volchenboum SL, Ratain MJ, O'Donnell PH. Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system. J Biomed Inform. 2017 Nov; 75:110-121. PMID: 28963061.
      Citations: 18     Fields:    Translation:Humans
    58. Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA, Abraham P, Rosenberg JE. Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 09 28; 5(1):80. PMID: 28962591; PMCID: PMC5622592.
      Citations: 3     Fields:    
    59. Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 11; 18(11):1483-1492. PMID: 28967485.
      Citations: 501     Fields:    Translation:HumansCTClinical Trials
    60. Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017 Sep 14; 3(9):e172411. PMID: 28817753; PMCID: PMC5824288.
      Citations: 381     Fields:    Translation:HumansCTClinical Trials
    61. Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA, Abraham P, Rosenberg JE. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 08 15; 5(1):68. PMID: 28807024; PMCID: PMC5557323.
      Citations: 37     Fields:    Translation:Humans
    62. O'Donnell PH, Wadhwa N, Danahey K, Borden BA, Lee SM, Hall JP, Klammer C, Hussain S, Siegler M, Sorrentino MJ, Davis AM, Sacro YA, Nanda R, Polonsky TS, Koyner JL, Burnet DL, Lipstreuer K, Rubin DT, Mulcahy C, Strek ME, Harper W, Cifu AS, Polite B, Patrick-Miller L, Yeo KT, Leung E, Volchenboum SL, Altman RB, Olopade OI, Stadler WM, Meltzer DO, Ratain MJ. Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing. Clin Pharmacol Ther. 2017 Nov; 102(5):859-869. PMID: 28398598; PMCID: PMC5636653.
      Citations: 33     Fields:    Translation:Humans
    63. Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS, Field JR, Weitzel KW, Cooper-DeHoff RM, Cavallari LH, O'Donnell PH, Altman RB, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, Johnson JA, Relling MV, Wang L, Weinshilboum RM, Shuldiner AR, Freimuth RR, Pharmacogenomics Research Network Translational Pharmacogenetics Program. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. Clin Pharmacol Ther. 2017 Sep; 102(3):502-510. PMID: 28090649; PMCID: PMC5511786.
      Citations: 72     Fields:    Translation:Humans
    64. Lee YM, McKillip RP, Borden BA, Klammer CE, Ratain MJ, O'Donnell PH. Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation. Pharmacogenet Genomics. 2017 05; 27(5):179-189. PMID: 28267054; PMCID: PMC5478379.
      Citations: 20     Fields:    Translation:Humans
    65. McKillip RP, Borden BA, Galecki P, Ham SA, Patrick-Miller L, Hall JP, Hussain S, Danahey K, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, Stadler WM, Ratain MJ, Meltzer DO, O'Donnell PH. Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program. Clin Pharmacol Ther. 2017 07; 102(1):106-114. PMID: 27981566; PMCID: PMC5474215.
      Citations: 11     Fields:    Translation:Humans
    66. Leung EKY, Agolini E, Pei X, Melis R, McMillin GA, Friedman PN, Peterson P, Danahey K, O'Donnell PH, Yeo KJ. Validation of an Extensive CYP2D6 Assay Panel Based on Invader and TaqMan Copy Number Assays. J Appl Lab Med. 2017 Mar 01; 1(5):471-482. PMID: 33379799.
      Citations: 4     Fields:    
    67. Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, Juco J, Lunceford J, Saraf S, Perini RF, O'Donnell PH. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017 Feb; 18(2):212-220. PMID: 28081914.
      Citations: 152     Fields:    Translation:HumansCTClinical Trials
    68. Sweis RF, Medved M, Towey S, Karczmar GS, Oto A, Szmulewitz RZ, O'Donnell PH, Fishkin P, Karrison T, Stadler WM. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212. PMID: 27634566; PMCID: PMC5315677.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    69. Sethakorn N, O'Donnell PH. Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma. BJU Int. 2016 Nov; 118(5):681-691. PMID: 27271022.
      Citations: 6     Fields:    Translation:Humans
    70. Morrison G, Lenkala D, LaCroix B, Ziliak D, Abramson V, Morrow PK, Forero A, Van Poznak C, Rugo HS, Nanda R, O'Donnell PH, Huang RS. Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. Oncotarget. 2016 Jun 21; 7(25):38359-38366. PMID: 27224917; PMCID: PMC5122395.
      Citations: 2     Fields:    Translation:HumansCells
    71. Hussain S, Kenigsberg BB, Danahey K, Lee YM, Galecki PM, Ratain MJ, O'Donnell PH. Disease-drug database for pharmacogenomic-based prescribing. Clin Pharmacol Ther. 2016 08; 100(2):179-90. PMID: 26940584; PMCID: PMC5570547.
      Citations: 10     Fields:    Translation:Humans
    72. Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016 09 10; 34(26):3119-25. PMID: 27269937; PMCID: PMC5569690.
      Citations: 377     Fields:    Translation:HumansCTClinical Trials
    73. Choudhury NJ, Campanile A, Antic T, Yap KL, Fitzpatrick CA, Wade JL, Karrison T, Stadler WM, Nakamura Y, O'Donnell PH. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol. 2016 06 20; 34(18):2165-71. PMID: 27044931; PMCID: PMC5569685.
      Citations: 76     Fields:    Translation:HumansCTClinical Trials
    74. Espina C, Jenkins I, Taylor L, Farah R, Cho E, Epworth J, Coleman K, Pinelli J, Mentzer S, Jarrett L, Gooley T, O'Donnell P, Hirsch IB, Bar M. Blood glucose control using a computer-guided glucose management system in allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplant. 2016 Jul; 51(7):973-9. PMID: 27042836.
      Citations: 4     Fields:    Translation:Humans
    75. O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, Stadler WM, Bajorin DF. Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clin Genitourin Cancer. 2016 12; 14(6):511-517. PMID: 27150640; PMCID: PMC5018246.
      Citations: 2     Fields:    Translation:Humans
    76. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R, Retz MM, Perez-Gracia JL. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 07; 387(10031):1909-20. PMID: 26952546; PMCID: PMC5480242.
      Citations: 1643     Fields:    Translation:HumansCTClinical Trials
    77. O'Donnell PH, Danahey K, Ratain MJ. The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone. Clin Pharmacol Ther. 2016 Apr; 99(4):401-4. PMID: 26756170; PMCID: PMC4830348.
      Citations: 6     Fields:    Translation:Humans
    78. Olsburgh J, Zakri RH, Horsfield C, Collins R, Fairweather J, O'Donnell P, Koffman G. TCC in Transplant Ureter--When and When Not to Preserve the Transplant Kidney. Am J Transplant. 2016 Feb; 16(2):704-11. PMID: 26731492.
      Citations: 5     Fields:    Translation:Humans
    79. Posadas EM, Ahmed RS, Karrison T, Szmulewitz RZ, O'Donnell PH, Wade JL, Shen J, Gururajan M, Sievert M, Stadler WM. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93. PMID: 26493492; PMCID: PMC4904773.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    80. Choudhury NJ, Kiyotani K, Yap KL, Campanile A, Antic T, Yew PY, Steinberg G, Park JH, Nakamura Y, O'Donnell PH. Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer. Eur Urol Focus. 2016 Oct; 2(4):445-452. PMID: 28723478.
      Citations: 43     Fields:    
    81. Wymer KM, Antic T, O'Donnell PH. Case Report of a Rare Presentation of Urothelial Carcinoma With Gastric Metastasis. Clin Genitourin Cancer. 2016 Feb; 14(1):e111-4. PMID: 26456403.
      Citations: 1     Fields:    Translation:Humans
    82. O'Donnell PH, Karovic S, Karrison TG, Janisch L, Levine MR, Harris PJ, Polite BN, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9. PMID: 26199386; PMCID: PMC4677671.
      Citations: 1     Fields:    Translation:Humans
    83. Milstone DS, Ilyama M, Chen M, O'Donnell P, Davis VM, Plutzky J, Brown JD, Haldar SM, Siu A, Lau AC, Zhu SN, Basheer MF, Collins T, Jongstra-Bilen J, Cybulsky MI. Differential role of an NF-?B transcriptional response element in endothelial versus intimal cell VCAM-1 expression. Circ Res. 2015 Jul 03; 117(2):166-77. PMID: 26034041; PMCID: PMC4758452.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    84. Kaufman AL, Spitz J, Jacobs M, Sorrentino M, Yuen S, Danahey K, Saner D, Klein TE, Altman RB, Ratain MJ, O'Donnell PH. Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clin Proc. 2015 Jun; 90(6):716-29. PMID: 26046407; PMCID: PMC4475352.
      Citations: 18     Fields:    Translation:Humans
    85. Kano S, Yuan M, Cardarelli RA, Maegawa G, Higurashi N, Gaval-Cruz M, Wilson AM, Tristan C, Kondo MA, Chen Y, Koga M, Obie C, Ishizuka K, Seshadri S, Srivastava R, Kato TA, Horiuchi Y, Sedlak TW, Lee Y, Rapoport JL, Hirose S, Okano H, Valle D, O'Donnell P, Sawa A, Kai M. Clinical utility of neuronal cells directly converted from fibroblasts of patients for neuropsychiatric disorders: studies of lysosomal storage diseases and channelopathy. Curr Mol Med. 2015; 15(2):138-45. PMID: 25732146; PMCID: PMC4428755.
      Citations: 6     Fields:    Translation:HumansCells
    86. Sorrentino MJ, O'Donnell PH. Pharmacogenomics and cardiology: improving treatment with existing drugs. Pharmacogenomics. 2015; 16(11):1223-6. PMID: 26369612.
      Citations: 1     Fields:    Translation:Humans
    87. Yap KL, Kiyotani K, Tamura K, Antic T, Jang M, Montoya M, Campanile A, Yew PY, Ganshert C, Fujioka T, Steinberg GD, O'Donnell PH, Nakamura Y. Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clin Cancer Res. 2014 Dec 15; 20(24):6605-17. PMID: 25316812; PMCID: PMC4268280.
      Citations: 46     Fields:    Translation:HumansCells
    88. O'Donnell PH. Unleashing the power of preemptive pharmacogenomics. Clin Adv Hematol Oncol. 2014 Oct; 12(10):695-7. PMID: 25658895.
      Citations:    Fields:    Translation:Humans
    89. Fang H, Liu X, Choudhury N, Kubo M, Im HK, Konkashbaev A, Cox NJ, Ratain MJ, Nakamura Y, O'Donnell PH, Ramírez J. Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Pharmacogenomics J. 2014 Dec; 14(6):564-72. PMID: 24980783; PMCID: PMC4237721.
      Citations: 16     Fields:    Translation:HumansCells
    90. Petri CR, O'Donnell PH, Cao H, Artz AS, Stock W, Wickrema A, Hard M, van Besien K. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014 Dec; 55(12):2866-73. PMID: 24564572; PMCID: PMC4477686.
      Citations: 9     Fields:    Translation:Humans
    91. Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G, Niegisch G. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2014 May; 113(5b):E137-43. PMID: 24219029.
      Citations: 17     Fields:    Translation:Humans
    92. O'Donnell PH, Danahey K, Jacobs M, Wadhwa NR, Yuen S, Bush A, Sacro Y, Sorrentino MJ, Siegler M, Harper W, Warrick A, Das S, Saner D, Corless CL, Ratain MJ. Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project". Am J Med Genet C Semin Med Genet. 2014 Mar; 166C(1):68-75. PMID: 24616296; PMCID: PMC4000170.
      Citations: 58     Fields:    Translation:Humans
    93. Dolan ME, Maitland ML, O'Donnell PH, Nakamura Y, Cox NJ, Ratain MJ. Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science. Pharmacogenomics. 2013 Sep; 14(12):1383-7. PMID: 24024891; PMCID: PMC4022693.
      Citations: 5     Fields:    Translation:Humans
    94. McDermott AM, Kidd P, Gately M, Casey R, Burke H, O'Donnell P, Kirrane F, Dinneen SF, O'Brien T. Restructuring of the Diabetes Day Centre: a pilot lean project in a tertiary referral centre in the West of Ireland. BMJ Qual Saf. 2013 Aug; 22(8):681-8. PMID: 23722055.
      Citations: 8     Fields:    Translation:Humans
    95. Galsky MD, Hendricks R, Svatek R, Bangs R, Hoffman-Censits J, Clement J, Dreicer R, Guancial E, Hahn N, Lerner SP, O'Donnell PH, Quale DZ, Siefker-Radtke A, Shipley W, Sonpavde G, Vaena D, Vinson J, Rosenberg J. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 2013 Jun 01; 119(11):1994-8. PMID: 23456777.
      Citations: 8     Fields:    Translation:Humans
    96. Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R, Bick D, Bottinger EP, Brilliant MH, Eng C, Frazer KA, Korf B, Ledbetter DH, Lupski JR, Marsh C, Mrazek D, Murray MF, O'Donnell PH, Rader DJ, Relling MV, Shuldiner AR, Valle D, Weinshilboum R, Green ED, Ginsburg GS. Implementing genomic medicine in the clinic: the future is here. Genet Med. 2013 Apr; 15(4):258-67. PMID: 23306799; PMCID: PMC3835144.
      Citations: 248     Fields:    Translation:Humans
    97. Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 2013 Apr; 63(4):717-23. PMID: 23206856; PMCID: PMC4127896.
      Citations: 59     Fields:    Translation:Humans
    98. Chang SS, Dinney CP, Donat SM, Dahm P, Gore JL, Lotan Y, Parekh DJ, Solit DB, O'Donnell PH, Feng FY, Hansel D, Milowsky MI. 12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report. Urol Oncol. 2012 Nov-Dec; 30(6):944-7. PMID: 23218073.
      Citations: 1     Fields:    Translation:Humans
    99. O'Donnell PH. Bladder cancer pharmacogenomics: recent insights and future perspectives. Pharmacogenomics. 2012 Nov; 13(14):1553-6. PMID: 23148629.
      Citations: 3     Fields:    Translation:Humans
    100. O'Donnell PH, Bush A, Spitz J, Danahey K, Saner D, Das S, Cox NJ, Ratain MJ. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther. 2012 Oct; 92(4):446-9. PMID: 22929923; PMCID: PMC4482357.
      Citations: 83     Fields:    Translation:Humans
    101. Thakar MS, Bonfim C, Sandmaier BM, O'Donnell P, Ribeiro L, Gooley T, Deeg HJ, Flowers ME, Pasquini R, Storb R, Woolfrey AE, Kiem HP. Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia. Pediatr Hematol Oncol. 2012 Sep; 29(6):568-78. PMID: 22839094; PMCID: PMC3622043.
      Citations: 9     Fields:    Translation:HumansCells
    102. O'Donnell PH, Stadler WM. Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II? Clin Cancer Res. 2012 May 15; 18(10):2809-16. PMID: 22427349; PMCID: PMC3354016.
      Citations: 4     Fields:    Translation:Humans
    103. Pai RK, van Besien K, Hart J, Artz AS, O'Donnell PH. Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1552-7. PMID: 22280517; PMCID: PMC4482341.
      Citations: 10     Fields:    Translation:Humans
    104. O'Donnell PH, Ratain MJ. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol. 2012 Apr; 6(2):251-9. PMID: 22321460; PMCID: PMC5528362.
      Citations: 29     Fields:    Translation:HumansCells
    105. O'Donnell PH, Stark AL, Gamazon ER, Wheeler HE, McIlwee BE, Gorsic L, Im HK, Huang RS, Cox NJ, Dolan ME. Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer. 2012 Aug 15; 118(16):4063-73. PMID: 22864933; PMCID: PMC3413892.
      Citations: 17     Fields:    Translation:HumansPHPublic Health
    106. van Besien K, Stock W, Rich E, Odenike O, Godley LA, O'Donnell PH, Kline J, Nguyen V, Del Cerro P, Larson RA, Artz AS. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012 Jun; 18(6):913-21. PMID: 22079470; PMCID: PMC3423318.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    107. Ward JE, Karrison T, Chatta G, Hussain M, Shevrin D, Szmulewitz RZ, O'Donnell PH, Stadler WM, Posadas EM. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92. PMID: 22006050; PMCID: PMC4312616.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    108. Wheeler HE, Gamazon ER, Stark AL, O'Donnell PH, Gorsic LK, Huang RS, Cox NJ, Dolan ME. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2013 Feb; 13(1):35-43. PMID: 21844884; PMCID: PMC3370147.
      Citations: 38     Fields:    Translation:HumansCells
    109. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Mi S, O'Donnell PH, Fraiman YS, Das S, Cox NJ, Lu Y, Macgregor S, Goode EL, Vierkant RA, Fridley BL, Hogdall E, Kjaer SK, Jensen A, Moysich KB, Grasela M, Odunsi K, Brown R, Paul J, Lambrechts D, Despierre E, Vergote I, Gross J, Karlan BY, Defazio A, Chenevix-Trench G, Australian Ovarian Cancer Study Group, Dolan ME. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011 Aug 15; 17(16):5490-500. PMID: 21705454; PMCID: PMC3160494.
      Citations: 43     Fields:    Translation:HumansCells
    110. O'Donnell PH. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int. 2011 Oct; 108(8):1284-5. PMID: 21418138.
      Citations: 2     Fields:    Translation:Humans
    111. Ziliak D, O'Donnell PH, Im HK, Gamazon ER, Chen P, Delaney S, Shukla S, Das S, Cox NJ, Vokes EE, Cohen EE, Dolan ME, Huang RS. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res. 2011 May; 157(5):265-72. PMID: 21497773; PMCID: PMC3079878.
      Citations: 32     Fields:    Translation:HumansCells
    112. Gamazon ER, Im HK, O'Donnell PH, Ziliak D, Stark AL, Cox NJ, Dolan ME, Huang RS. Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity. Mol Cancer Ther. 2011 Mar; 10(3):472-80. PMID: 21252287; PMCID: PMC3079551.
      Citations: 4     Fields:    Translation:HumansCells
    113. O'Donnell PH, Posadas EM. Editorial comment. Urology. 2011 Jan; 77(1):165-6. PMID: 21195839.
      Citations:    Fields:    Translation:Humans
    114. Stark AL, Zhang W, Zhou T, O'Donnell PH, Beiswanger CM, Huang RS, Cox NJ, Dolan ME. Population differences in the rate of proliferation of international HapMap cell lines. Am J Hum Genet. 2010 Dec 10; 87(6):829-33. PMID: 21109222; PMCID: PMC2997375.
      Citations: 14     Fields:    Translation:HumansCells
    115. O'Donnell PH, Artz AS, Undevia SD, Pai RK, Del Cerro P, Horowitz S, Godley LA, Hart J, Innocenti F, Larson RA, Odenike OM, Stock W, Van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9. PMID: 20919852; PMCID: PMC4477684.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    116. O'Donnell PH, Undevia SD, Stadler WM, Karrison TM, Nicholas MK, Janisch L, Ratain MJ. A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs. 2012 Apr; 30(2):604-10. PMID: 20839028; PMCID: PMC3059335.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    117. O'Donnell PH, Gamazon E, Zhang W, Stark AL, Kistner-Griffin EO, Stephanie Huang R, Eileen Dolan M. Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet Genomics. 2010 May; 20(5):327-37. PMID: 20393316; PMCID: PMC2908307.
      Citations: 15     Fields:    Translation:HumansCells
    118. Stark AL, Zhang W, Mi S, Duan S, O'Donnell PH, Huang RS, Dolan ME. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010 Dec; 10(6):505-12. PMID: 20142840; PMCID: PMC2975793.
      Citations: 37     Fields:    Translation:HumansCells
    119. O'Donnell PH, Jensen A, Posadas EM, Bridge JA, Yeldandi AV, Yang XJ, Stadler WM, Al-Ahmadie H. Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nat Rev Urol. 2010 Feb; 7(2):110-4. PMID: 20145663.
      Citations: 4     Fields:    Translation:Humans
    120. O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009 Aug 01; 15(15):4806-14. PMID: 19622575; PMCID: PMC2774468.
      Citations: 120     Fields:    Translation:Humans
    121. O'Donnell PH, Swanson K, Josephson MA, Artz AS, Parsad SD, Ramaprasad C, Pursell K, Rich E, Stock W, van Besien K. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1038-1048.e1. PMID: 19660716; PMCID: PMC2723723.
      Citations: 27     Fields:    Translation:HumansCells
    122. O'Donnell PH, Stadler WM. The role of chemotherapy in upper tract urothelial carcinoma. Adv Urol. 2009; 419028. PMID: 19190766; PMCID: PMC2630419.
      Citations: 8     
    123. O'Donnell PH, Artz AS, Undevia SD, Hart J, van Besien K. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoetic stem cell transplantation (alloHCT). J Clin Oncol. 2008 May 20; 26(15_suppl):7042. PMID: 27949605.
    124. O'Donnell PH, Ratain MJ. Evaluating the activity of temsirolimus in neuroendocrine cancer. Br J Cancer. 2007 Jan 15; 96(1):177; author reply 178-9. PMID: 17164757; PMCID: PMC2360210.
      Citations: 4     Fields:    Translation:Humans
    125. Jayawardene SA, Covic A, Malikian N, Owen WJ, O'Donnell P, Taylor J, Koffman GC, Goldsmith DJ. Atypical post-renal transplantation hyperparathyroidism--further support for "removing all enlarged glands". Rev Med Chir Soc Med Nat Iasi. 2003 Jul-Sep; 107(3):636-40. PMID: 14756077.
      Citations: 1     Fields:    Translation:Humans
    126. O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia. 2002 May; 16(5):902-10. PMID: 11986953.
      Citations: 32     Fields:    Translation:HumansCells
    127. Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB, Zahurak ML, Fuller D, Miller CB, Noga SJ, Fuchs E, Flinn IW, O'Donnell P, Seifter EJ, Mann RB, Jones RJ. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol. 2001 Dec 01; 19(23):4314-21. PMID: 11731514.
      Citations: 36     Fields:    Translation:Humans
    O'Donnell's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (440)
    Co-Authors (87)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors